The recent acquisition of Credit Suisse by UBS Group AG is reshaping Switzerland’s banking industry. According to the Swiss National Bank, the takeover has prompted borrowers to turn to smaller, domestically oriented institutions for credit.

Swiss National Bank recently reduced its holding in Rhythm Pharmaceuticals by a modest 900 shares during the first quarter, as disclosed in a new SEC filing. Despite the small adjustment, the bank retains a significant position in the company.

Swiss National Bank has reduced its investment in BCE, Inc. by 2.0%, selling off 4,200 shares according to its latest SEC filing. Despite this reduction, the bank still holds 207,709 shares, valued at $4.77 million.